Forte Biosciences, Inc.FBRXNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-58.76%
↑ 52% above average
Average (34q)
-121.37%
Historical baseline
Range
High:109.31%
Low:-1614.55%
Volatility
-1420.3%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -58.76% |
| Q2 2025 | 28.19% |
| Q1 2025 | -119.34% |
| Q4 2024 | 14.81% |
| Q3 2024 | 32.68% |
| Q2 2024 | -64.25% |
| Q1 2024 | -22.30% |
| Q4 2023 | 37.54% |
| Q3 2023 | -13.08% |
| Q2 2023 | -31.79% |
| Q1 2023 | -38.79% |
| Q4 2022 | -44.29% |
| Q3 2022 | -13.34% |
| Q2 2022 | -20.13% |
| Q1 2022 | 23.80% |
| Q4 2021 | 57.15% |
| Q3 2021 | -33.97% |
| Q2 2021 | -21.22% |
| Q1 2021 | -5.52% |
| Q4 2020 | 10.28% |
| Q3 2020 | 85.59% |
| Q2 2020 | -1614.55% |
| Q1 2020 | 78.12% |
| Q4 2019 | -1254.24% |
| Q3 2019 | -8.74% |
| Q2 2019 | 47.01% |
| Q1 2019 | 93.79% |
| Q4 2018 | -1438.96% |
| Q3 2018 | 109.31% |
| Q2 2018 | -19.31% |
| Q1 2018 | -20.20% |
| Q4 2017 | -9.76% |
| Q3 2017 | -12.54% |
| Q2 2017 | -1.16% |
| Q1 2017 | 0.00% |